Health
PARP inhibitor, stenoparib inhibits pre- and post-entry processes of SARS-CoV-2 in vitro – News-Medical.Net
A team of researchers from the Northern Arizona University evaluated a new PARP inhibitor, stenoparib, which has recently advanced to Stage II of clinical trials…
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the novel coronavirus, originated from Wuhan, China, in late December 2019 and rapidly spread across the globe, progressing into a devastating pandemic. To date, the COVID-19 pandemic has caused 54.3 million infections and over 1.31 million deaths worldwide.
In the absence of a vaccine, COVID-19 can continue to cause significant morbidity and mortality
Coronavirus disease (COVID-19) affects the upper and lower respiratory systems and…
-
Noosa News20 hours agoQueensland government to review greenhouse gas emission reduction targets
-
Noosa News21 hours agoYoung voices shape Sunshine Coast’s future
-
Business21 hours ago2 Low Cost Active ASX ETFs to consider
-
Noosa News18 hours agoStar Entertainment signs $300m lifeline deal with US gaming giant Bally’s